IDEAYA Biosciences, Inc. (IDYA): who owns it and who trades it
As of Nov 16, 2026, IDYA insiders reported 3 open-market sales worth $1.4M and 1 purchase worth $1.6M in the last 12 months, with 72% of the sale value made under pre-set 10b5-1 plans. The largest seller was Yujiro S Hata (CEO), with $985K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling IDEAYA Biosciences
From the latest filingsOverall: more selling than buying. Famous investors mostly sold. Funds and insiders were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IDYA
283 funds and institutions reported IDYA shares worth $3.9B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 16.1%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 14.11M | 16.06% | $526M | +7% |
| BlackRock, Inc. | 8.89M | 10.12% | $331M | +5% |
| Jupiter Topco LLC | 8.58M | 9.77% | $320M | – |
| Capital Research Global Investors | 5.34M | 6.08% | $199M | +4% |
| Baker Bros. Advisors LP | 5.01M | 5.70% | $187M | +27% |
| State Street Corp | 4.55M | 5.18% | $170M | +20% |
| Vanguard Capital Management LLC | 4.13M | 4.70% | $154M | +11% |
| California State Teachers Retirement System | 3.50M | 3.98% | $93.9M | +3522% |
| Logos Global Management LP | 3.00M | 3.41% | $112M | -13% |
| Adage Capital Partners Gp, L.l.c. | 2.72M | 3.09% | $101M | -4% |
| Deerfield Management Company, L.P. | 2.71M | 3.09% | $101M | +77% |
| Geode Capital Management, LLC | 2.43M | 2.76% | $90.4M | -3% |
| T. Rowe Price Associates | 2.21M | 2.51% | $82.3M | +68% |
| Morgan Stanley | 1.93M | 2.20% | $72M | +4% |
| Dimensional Fund Advisors LP | 1.66M | 1.89% | $61.9M | +25% |
| Alliancebernstein L.P. | 1.63M | 1.85% | $54.2M | +1515% |
| Fiera Capital Corp | 1.45M | 1.65% | $53.9M | -43% |
| Federated Hermes, Inc. | 1.43M | 1.63% | $53.4M | -52% |
| GSK plc | 1.33M | 1.52% | $49.7M | No change |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.27M | 1.45% | $47.3M | +15% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IDYA insiders reported $1.6M of open-market purchases and $1.4M of sales. 72% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Yujiro S Hata | CEO | Sale plan | 25,538 | $37.39 | $955K | Form 4 |
| Oct 6, 2026 | Yujiro S Hata | CEO | Sale plan | 800 | $38.26 | $30.6K | Form 4 |
| Jul 7, 2026 | Briseno Andres Ruiz | Chief Accounting Officer | Sale | 9,550 | $40.01 | $382K | Form 4 |
| Mar 2, 2026 | Jeffrey Stein | Director | Purchase | 50,000 | $32.96 | $1.6M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jeffrey Stein | Director | $1.6M | – | Mar 2, 2026 |
| Yujiro S Hata | President and CEO, Director | – | $985K | Oct 6, 2026 |
| Briseno Andres Ruiz | Chief Accounting Officer | – | $382K | Jul 7, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IDYA short interest
Moderate short interest. 8.5% of IDYA shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 30%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.24M IDYA shares were sold short, 8.5% of the shares outstanding, down 9.3% from the report before. At the average daily volume of 928,512 shares, buying them all back would take about 8.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.24M | 8.54% | -9% | 928,512 | 8.9 |
| Oct 15, 2026 | 9.08M | 9.41% | -1% | 754,634 | 12.0 |
| Sep 30, 2026 | 9.18M | 9.52% | -8% | 1.09M | 8.4 |
| Sep 15, 2026 | 9.93M | 10.29% | -2% | 575,248 | 17.3 |
| Aug 31, 2026 | 10.10M | 10.47% | -3% | 827,360 | 12.2 |
| Aug 14, 2026 | 10.40M | 10.78% | +3% | 629,939 | 16.5 |
| Jul 31, 2026 | 10.11M | 10.48% | +6% | 766,531 | 13.2 |
| Jul 15, 2026 | 9.57M | 10.90% | -7% | 1.11M | 8.6 |
| Jun 30, 2026 | 10.33M | 11.76% | -3% | 1.70M | 6.1 |
| Jun 15, 2026 | 10.63M | 12.10% | -6% | 1.41M | 7.5 |
| May 29, 2026 | 11.34M | 12.90% | -3% | 693,874 | 16.3 |
| May 15, 2026 | 11.70M | 13.32% | No change | 838,482 | 14.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
IDEAYA Biosciences company events
IDEAYA Biosciences filed 15 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 3, 2026.
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 23, 2026AnnouncementThe Company’s Board of Directors elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as the Board’s Lead Independent Director. Filing
- Jun 10, 2026AnnouncementIDEAYA Biosciences, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC, TD Securities (USA) LLC, UBS Securities LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters named therein, pursuant to which the Company agreed to issue and… Filing
- Jun 3, 2026AnnouncementIDEAYA Biosciences, Inc. announced it has entered into a clinical collaboration with F. Hoffmann-La Roche Ltd to evaluate the efficacy and safety of IDE892, its investigational, potential best-in-class PRMT5 inhibitor, in combination with Roche’s RG6505, a pan-RAS inhibitor, in patients with… Filing
- Jun 1, 2026AnnouncementIDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO On June 1, 2026, the Company and Les Laboratoires Servier… Filing
- May 5, 2026AnnouncementIDEAYA Biosciences, Inc. filed with the Securities and Exchange Commission an automatic shelf registration statement on Form S-3ASR (Registration No. 333-295560) to replace its existing automatic shelf registration statement on Form S-3 (Registration No. 333-272936) filed with the SEC on June 26… Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 13, 2026AnnouncementMade another announcement. Filing
- Apr 9, 2026AnnouncementIDEAYA Biosciences, Inc. entered into a clinical collaboration agreement with AstraZeneca plc to evaluate the efficacy and safety of IDE849, the Company’s investigational, potential first-in-class DLL3 TOP1 antibody-drug conjugate, in combination with AstraZeneca’s Imfinzi ® (durvalumab), a… Filing
- Feb 17, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementIDEAYA Biosciences, Inc. provided a business update including an overview of key corporate objectives for 2026. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Dec 12, 2025AgreementEnded an important agreement. Filing
- Dec 5, 2025AnnouncementGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) communicated to IDEAYA Biosciences, Inc. its election to terminate the Collaboration, Option and License Agreement, dated June 15, 2020 (as amended, the “Agreement”). Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
IDEAYA Biosciences financials
Famous investors that hold IDYA
2 of the 50 well-known investors we track reported holding IDYA in their latest 13F filing. The largest position is Ken Fisher's, worth $31.1M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 810,671 | $31.1M | 0.0% | -5% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 13,156 | $505K | 0.0% | -71% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about IDEAYA Biosciences, Inc. (IDYA) stock
Who owns the most IDYA stock?
The largest reported owner of IDEAYA Biosciences, Inc. (IDYA) is FMR LLC (Fidelity), with 16.1% of the company. In total, 283 funds and institutions reported holding IDYA at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are IDYA insiders buying or selling?
In the last 12 months, IDYA insiders reported 1 open-market purchase worth $1.6M and 3 sales worth $1.4M. The latest trade was on Oct 6, 2026. See every trade.
What is the short interest in IDYA?
As of Oct 30, 2026, 8.24M IDYA shares were sold short, 8.5% of the shares outstanding, down 9.3% from the report before. At the average daily volume of 928,512 shares, buying them all back would take about 8.9 trading days (days to cover). See the history.
Which famous investors hold IDYA?
2 of the 50 well-known investors we track reported IDYA in their latest 13F filing, including Ken Fisher, Paul Tudor Jones. The largest position is worth $31.1M. See all holders.
Executive pay
IDEAYA Biosciences's chief executive was paid a total of $9.5M for the year ended Dec 31, 2025, down 44% from $16.9M the year before. In the last 12 months, IDEAYA Biosciences's executives and directors bought $1.6M of stock on the open market and sold $1.4M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.